Al-Jarrad Ahmad, Alouch Samhar Samer, Chawla Yogesh, Gonsalves Wilson I
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Blood Lymphat Cancer. 2025 Mar 24;15:1-10. doi: 10.2147/BLCTT.S492116. eCollection 2025.
T-cell engagers (TCEs) are engineered to bind both the CD3 subunit on T-cells and specific antigens on tumor cells, triggering T-cell activation and tumor cell lysis. TCEs targeting B-cell maturation antigen (BCMA) and G-protein-coupled receptor, class C, group 5, member D (GPRC5D) have demonstrated significant clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). As a monotherapy, TCEs have had overall response rates (ORRs) of over 60%, with deep and durable hematological responses. Common toxicities include cytokine release syndrome (CRS), infections, and on-target off-tumor effects. Ongoing research looks to enhance the efficacy and tolerability of TCEs for the next generation of products to play an even bigger role in treating patients with MM.
T细胞衔接器（TCEs）经过改造，能够同时结合T细胞上的CD3亚基和肿瘤细胞上的特定抗原，从而触发T细胞活化和肿瘤细胞裂解。靶向B细胞成熟抗原（BCMA）和G蛋白偶联受体C类第5组成员D（GPRC5D）的TCEs在复发/难治性多发性骨髓瘤（RRMM）的重度预处理患者中已显示出显著的临床活性。作为单一疗法，TCEs的总缓解率（ORR）超过60%，具有深度且持久的血液学缓解。常见毒性包括细胞因子释放综合征（CRS）、感染和靶向脱瘤效应。正在进行的研究旨在提高TCEs的疗效和耐受性，以便下一代产品在治疗MM患者中发挥更大作用。
